After being called out on some intellectual property claims late last year, Teva has fallen victim to the Federal Trade Commission’s (FTC’s) ongoing crusade against questionable drug patents.
Two prominent congressional Democrats this week wrote to eight pharmaceutical company CEOs, urging them to remove 130 patents ...
“There is no dispute that the Inhaler Patents contain no claim for the active ingredient at issue, albuterol sulfate. Amneal contends that the Inhaler Patents do not meet the requirement that ...
We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up to receive our free e-Newsbulletins Some states have laws and ethical rules regarding solicitation and ...
, opens new tab with the backing of the U.S. Federal Trade Commission convinced a New Jersey federal court on Monday to remove five Teva Pharmaceutical (TEVA.TA) , opens new tab patents from a U.S ...
Opinions expressed by Forbes Contributors are their own. The narrative around so-called junk fees, as the regulators began contemplating new restrictions, seemed to define the target as extra ...
Last week, the Federal Trade Commission provided its annual report to the Consumer Financial Protection Bureau on its enforcement and related activities in 2023 on the Truth in Lending Act (TILA ...
It’s hard to find bipartisan consensus among lawmakers in Congress these days. But there’s widespread agreement on calls for pharmaceutical patent reform. The steep prices of brand-name drugs ...
It seems it’s not only the Biden administration that believes regulating “junk fees” is popular with voters. Minnesota joins California as states that have passed their own junk fee legislation.
Nicole Narea covers politics and society for Vox. She first joined Vox in 2019, and her work has also appeared in Politico, Washington Monthly, and the New Republic. President Joe Biden has ...